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1. Introduction 
Preeclampsia, a hypertensive disorder that complicates approximately 3-5% of first 
pregnancies and is usually clinically manifested after 20 weeks of gestation, is a major cause of 
perinatal morbidity and mortality; also, neonates of preeclamptic mothers are prone to 
preterm birth, low birth weight for gestational age and fetal growth restriction [Goldman-
Wohl & Yagel, 2002]. Although the pathophysiologic process of preeclampsia is not fully 
elucidated, abnormal placentation, shallow endovascular invasion, placental hypoxia, 
maternal insulin resistance and diffuse endothelial dysfunction seem to be interconnected key 
events that may precede the clinical onset of the disease by weeks or months [Davison et al., 
2004]. In particular, impaired placental perfusion is evident even from the first trimester as it 
has been documented by the findings of both histologic and Doppler ultrasound findings of 
the uterine arteries and the altered levels of  placental derived biochemical markers as 
pregnancy-associated plasma protein (PAPP-A) [Poon et al., 2009a; Poon et al., 2009b].  
The insulin-like growth factor (IGF) system comprises the IGF peptides (IGF-I, IGF-II), the 
cellular IGF receptors (type I, type II), and a family of soluble high affinity IGF binding 
proteins (IGFBP-1 to IGFBP-6) which modulate the bioavailability and activity of the IGFs 
[Jones & Clemmons, 1994] (Figure 1). Since the discovery of the IGF system before 50 or so 
years, there is ample evidence for their role in cell proliferation, differentiation and 
migration and their anti-apoptotic properties as well; thus they are involved in several 
physiological and pathological processes during prenatal and postnatal life [Forbes & 
Westwood, 2008]. This review aims to critically evaluate the postulated role of IGF axis 
components in the pathogenesis of preeclampsia and to discuss the mechanisms through 
which these effects are mediated.  
1.1 The IGF system in pregnancy  
During pregnancy, several alterations are noted regarding the expression pattern and 
function of IGFs. According to a recent longitudinal study, the maternal serum levels of IGF-
I remain stable until 20 weeks and then increase whereas IGF-II values do not relatively 
change throughout gestation [Olausson et al., 2008]. Though in non-pregnant-individuals, 
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IGF-I is primarily derived from the liver, during gestation its main source is decidua under 
the stimulatory action of a specific growth hormone placental variant (PGH) that is 
produced by syncytiotrophoblast and extravillous trophoblast from the 7th or 8th week of 
gestation and gradually replaces pituitary growth hormone (GH) in the maternal 
circulation. PGH is implicated in the physiological adjustment to gestation by stimulating 
gluconeogenesis, lipolysis and anabolism and exercises its effects either indirectly by 
regulating IGF-I levels or in an autocrine/paracrine manner [Sifakis et al., 2009]. In plasma 
during postnatal life, most of the IGFs (75%) exist in a 140-k Da heterotrimeric complex 
consisting of IGFBP-3 and an -85 kDa protein, the acid-labile (ALS); when this complex 
dissociates, IGFs form smaller, binary complexes with the other IGFBPs while less than 1% 
of IGFs circulate in free biologically active form [Baxter, 1994].  
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Fig. 1. A simplified model of the components of the IGF axis and their role in placental 
development  
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Despite many similarities, IGFBPs have distinctive properties concerning their exact 
function, their constant hormonal and metabolic regulation, their structural features and the 
tissue distribution of their expression during the various stages of development. Although 
in the non-pregnant state, IGFBP-I is mainly produced in the liver, during pregnancy its 
predominant site of synthesis is the decidualized endometrium [Forbes & Westwood, 2008]. 
In particular, IGFBP-1 is increasing rapidly in maternal serum so as to be abundant in 
second- and third-trimester concomitantly with the second wave of trophoblast invasion 
until 35 weeks and then decrease thereafter till term [Olausson et al., 2008]. IGFBP-3, the 
most abundant binding protein for IGFs, provides a circulating storage reservoir for IGFs 
although its affinity may be decreased in gestation period. An endogenous pregnancy-
related serum IGFBP-3 proteolytic activity is considered a fundamental mechanism to 
increase bioactive IGFs [Lewitt et al., 1998]. Conflicting results have been reported regarding 
IGFBP-3 concentration throughout pregnancy probably as a result of different applied 
measurement methods; a recent longitudinal study reported that the maternal serum levels 
of IGFBP-3 remained stable and increased only after 35 weeks of gestation [Olausson et al., 
2008]. The exact impact of IGFBPs also depends on the posttranslational modification of the 
protein (e.g. phosphorylation, glycosylation, altered proteolysis) which is under rapid and 
dynamic regulation [Forbes & Westwood, 2008]. Specifically, the IGFBP-I gene has multiple 
regulatory elements in its promoter that synergize or act independently and it is strongly 
regulated by insulin though IGFBP-3 is primarily determined by GH [Powell et al., 1995]. 
Besides, IGFBPs, particularly IGFBP-1, -3 and -5, carry out IGF-independent actions 
including inhibition of cell growth and induction of apoptosis; however their downstream 
effects need further investigation [Cohen et al., 1993; Jones et al., 1993].   
The biological actions of both IGFs are mediated by binding to the two IGF receptors 
[Monzavi & Cohen, 2002]. The type I IGF receptor (IGF1R), a member of the protein 
tyrosine kinase receptor superfamily, is the main receptor for signal transduction and 
cellular action of the IGFs though the type II IGF receptor is identical to the mannose-6-
phosphate receptor which shuttles lysosomal enzymes and binds IGF-II and (to a lesser 
extent) IGF-I [Monzavi & Cohen, 2002]. Another type of receptor which is also expressed 
in the placenta and binds to IGF-II in fetal tissues with similar affinity to IGF1R is the 
insulin receptor (IR) that is structurally similar to IGF1R but with a distinct signaling 
pathway mainly mitogenic [Frasca et al., 1999].    
2. IGF system in fetal growth and preeclampsia  
2.1 The role of the IGF system in fetal growth  
An increasing wealth of literature including clinical and knockout studies in mice points to 
the crucial role of IGF axis in correct embryonic and placental development and growth. 
Regarding the role of IGF-I in fetoplacental growth, clinical studies based on the 
measurements in cord blood from healthy newborns demonstrated that birth weight is 
positively correlated with IGF levels and therefore, the levels are low and raised in small-for 
gestational-age (SGA) infants and large-for gestation-age (LGA) infants retrospectively 
[Giudice et al., 1995; Osorio et al., 1996; Boyne et al., 2003]. These clinical observations were 
further confirmed by studies using transgenic mice in which the mutation of the gene 
encoding either IGF-I or IGF-II resulted in restricted growth [Efstratiadis, 1998]. However, 
other research groups do not lend support to a relationship between total IGF-I and birth 
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weight [Chellakooty et al., 2003]. Surprisingly, increased transcription of IGF-I and IGF-II 
not essentially associated with a corresponding increase in proteins levels have also been 
noted in IUGR pregnancies interpreted as a compensatory  attempt against the inhibitory 
effect of either the enhanced level of IGFBPs and/or number of IGF2R or a response to 
impaired growth [Dalcik et al., 2001; Sheikh et al., 2001]. Alternatively, maternal diabetes 
seems to result in inverse changes of circulating fetal IGF-I and IGFBP-1 at birth leading to 
the proposal that a decrease in IGFBP-1 and to a lesser extent an increase in IGFs of cord 
blood samples may represent an important mechanism that contributes to macrosomia in 
these pregnancies [Lindsay et al., 2007].  
Additionally, extensive data are available on the involvement of the IGFBPs in the abnormal 
fetal growth and maturity, chiefly highlighting the role of IGFBP-1 & IGFBP-3 in this 
process. Several research groups support that IGFBP-1 concentrations in amniotic fluid, 
maternal serum and fetal cord blood are predictive of newborn birth weight in both humans 
and mice; particularly, a striking inverse correlation between IGFBP-1 levels and fetal size is 
established although it is not clarified if an elevated level of circulating IGFBP-I is sufficient 
to cause fetal growth retardation or it depends on IGF-I mediated cell proliferation [Chard 
1994; Crossey et al., 2002]. In contrast to IGFBP-1 and IGFBP-2 which correlate inversely 
with IGF-1 levels and birthweight, IGF-I and IGFBP-3 appear to be regulated in a 
coordinated manner, and show a significant positive relationship to parameters of fetal 
growth in both normal and complicated pregnancies despite the narrow reported conflicting 
results [Fant et al., 1993; Verhaeghe et al., 1993]. However, there are also reports of elevated 
IGFBP-3 levels in SGA infants and in low-birth weight offspring of mice over expressing the 
human IGFBP-3 gene [Holmes et al., 1997; Modric et al., 2001]. Also, disrupted IGF 
receptors’ expression can also negatively affect fetal growth as it is demonstrated by a recent 
study reporting severe fetal growth restriction in two infants with a heterozygous missense 
mutation in the IGFIR gene [Walenkamp et al., 2006]. On the contrary, IGF-2R is thought to 
clear the IGF-II from the circulation and this is obviously supported by studies showing that 
mice lacking the IGF2R have greater birth weights than wild-type littermates [Lau et al., 
1994; Efstratiadis, 1998].  
2.2 The role of IGF system in preeclampsia  
A central feature of preeclampsia is defective placentation expressed as shallow placental 
invasion limited to the superficial portion of decidua and abnormal remodeling of the 
endometrial vasculature due to failure of the conversion of the maternal spiral arteries into 
vessels of low resistance and high capacitance, as it has been supported by histological 
analysis of preeclamptic tissue specimens [Goldman-Wohl & Yagel, 2002]. Indirect evidence 
for impaired placental perfusion in pregnancies destined to develop preeclampsia has been 
provided by Doppler studies of the uterine arteries which showed increased pulsatility 
index (PI) from the first trimester of pregnancy [Martin et al., 2001; Poon et al., 2009b]. 
Immunohistochemical studies in human and animal placentas have meticulously 
demonstrated the placental synthesis of IGF system components; however, it is not accurate 
to draw conclusions for the development of human placenta based on animal models as the 
placenta is one of the very few organs that is unique to each species, both anatomically and 
functionally.  
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The evolutionary pattern of expression of IGFs, IGFBPs and IGF-1R genes in the developing 
human placenta and fetal membranes has been described from as early as 6 weeks’ gestation 
to term in order to detect the exact expression cite of each peptide and the potential cite of 
its action [Han et al., 1996]. Functionally, IGF axis appears to be involved in many aspects of 
placental development and metabolism both in uncomplicated and preeclamptic 
pregnancies though the exact signaling pathways have yet to be determined [Hills et al., 
2004]. Studies based on cultured human trophoblast cells and cell lines propose that IGFs 
promote proliferation, regulate trophoblast migration and the differentiation of 
cytotrophoblasts into syncytiotrophoblasts and extravillous cells, enhance the proliferation 
and survival of placental fibroblast, exhibit anti-apoptotic effect and mediate nutrient 
availability at the fetoplacental unit  [Lacey et al., 2002; Smith et al., 2002; Miller et al., 2005].  
To date, the majority of published studies carried out to describe the alteration profile of 
the components of the IGF axis in preeclampsia are based on assays in maternal serum 
specimens. The extracted results do not always reflect the placental expression of the 
studied factors as the liver is an additional source of circulating factors in maternal serum 
or other posttranscriptional and/or posttranslational modifications maybe involved as it 
has been proposed for FGR placentas [Shin et al., 2003]. Regarding the early stages of 
gestation, when preeclampsia is in a pre-symptomatic stage, the published results are 
mainly focused on IGFs, IGFBP-1 and IGFBP-3 and are limited compared to the later 
stages where there is also discrepancy but to a lesser extent. The comparative analysis of 
these studies is a challenging task for several reasons such as the conflicting results, the 
differences in the study design, the sampling weeks, the dissimilar distribution of the 
severity and the subtypes of preeclampsia analyzed, the selection of the study population, 
the portion of each factor measured (total, bounded or free form) and the limitations of 
each study. Differentiations in the sensitivity and specificity of assays applied and the 
adjustment for confounding factors may also account for some of the variations observed 
across studies.  
2.3 IGFs  
Several studies have accessed the interesting way in which the trophoblast-derived IGF-II 
and the decidual-derived IGFBP-I interact in the uterine environment in a paracrine manner 
and how this modulates trophoblast invasion in preeclampsia [Giudice  et al., 1999; Irwin et 
al., 2001; Shin et al., 2003]. IGF-II m RNA is highly expressed by trophoblast with the 
greatest concentrations expressed at the invading front even from the 6th week of gestation, 
indicating a possible role of this peptide in cytotrophoblastic proliferation and the 
decidualization of the maternal stroma while IGFBP-I is the most plentifully expressed 
binding protein in the decidualized endometrium under the stimulatory effect of HCG and 
progesterone [Moy et al., 1996; Fowler et al., 2000]. Interestingly, the mean IGFBP-I m RNA 
and protein level were significantly elevated in preeclampsia compared with uncomplicated 
pregnancies in positive correlation with the severity of the disease [Shin et al., 2003]. In line 
with this observation, Giudice et al indicated the possible involvement of this protein in 
abnormal placentation and the same research group supported that the decidual derived 
IGFBP-I may lead to high maternal serum concentrations due to the increased vascular 
permeability of the leaky capillaries common in preeclampsia [Giudice et al., 1997]. As for 
the IGF-II, a significant decrease more profound in severe preeclampsia was confirmed both 
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in m RNA and protein expression in preeclamptic placentas, by different research groups 
[Giudice et al., 1999; Shin et al., 2003]. Published data indicate that IGF-II stimulates 
proliferation and migration of cytotrophoblasts, regulates nutrient exchange but is not 
implicated in placental cell differentiation so the decreased levels of this factor may alter the 
invasive nature of cytotrophoblasts resulting in placental dysfunction [Shin et al., 2003]. On 
the contrary, Gratton et al. observed increased IGF-II m RNA abundance in the intermediate 
trophoblast surrounding placental infracts suggesting a role in placental repair or 
remodeling and decreased IGFBP-1 m RNA levels [Gratton et al., 2002]. Besides, in an in-
vivo analysis of term placentas of gestations complicated by acute or chronic hypoxic 
ischemia, IGF-2 m RNA levels were elevated only in chronic hypoxia in contrast to IGF-I 
and PGH m RNA levels which did not significantly change, maybe as a part of a local 
metabolic adjustment [Trollmann et al., 2007].   
IGF-II level in maternal serum is less investigated and up to now it seems not to 
significantly vary between preeclamptic and normotensive women [Giudice et al., 1997; 
Lewitt et al., 1998]. A possible explanation is that it does not share exactly the same 
regulation pattern with IGF-I as it is not primarily GH-dependent [Giudice et al., 1997]. On 
the contrary, there is a remarkable inconsistency among published results about the 
concentration of IGF-I in pregnancies destined to be preeclamptic. The only prospective 
cohort study that measured free rather than total IGF-I and IGFBP-1 levels and made 
adjustment for several confounding factors such as gestational age at blood collection, 
maternal age, parity, and prepregnacy adiposity, reported lower concentrations of these 
factors apparent in first trimester [Ning et al., 2004]. The attenuation of IGF-1 synthesis may 
result from impaired PGH synthesis as a consequence of the compromised placentation 
observed in preeclampsia [Ning et al., 2004]. Although several cross-sectional and 
longitudinal studies have found a positive correlation between serum PGH and IGF-1 
values in pregnancies with fetoplacental unit disorders, our recent results do not provide 
support to the upper speculation as lower IGF-I levels but no alteration in PGH levels were 
observed in 11-13 weeks of gestation in pregnancies subsequently complicated by 
preeclampsia of either early or late onset [Sifakis et al., 2010; Sifakis et al. 2011a]. To 
elucidate this matter, it would be of special interest to investigate the range of the IGF-I 
levels in parallel with the change of PGH production throughout the disease transition from 
a latent preclinical stage to the clinically manifested preeclampsia. 
Given that IGF-I acts positively on insulin sensitivity and the tissue availability of IGF-I is a 
significant determinant of insulin sensitivity in patients with essential hypertension, it could 
be presumed that decreased circulating levels of this factor would be responsible, at least in 
part, for insulin resistance in preeclampsia [Kocyigit et al., 2004]. However, Bartha et al. 
supported that increased insulin resistance is associated with gestational hypertension 
rather than preeclampsia and that there is no significant correlation between insulin 
sensitivity index and serum IGF-I levels [Bartha et al., 2002]. Also, there is no obvious 
explanation for the findings of other studies which recruited women before the clinical 
manifestation of the disease and reported that the maternal serum levels of IGF-I were either 
increased or not significantly altered [Hubinette et al., 2003; Vatten et al., 2008]. Based on a 
similar prospective approach, an increase in IGF-I from the first to second trimester and not 
within each trimester was associated with higher risk of preterm preeclampsia possibly 
interpreted as a compensatory mechanism to preserve fetal growth or/and a possible 
www.intechopen.com
 
Recent Insights into the Role of the Insulin-Like Growth Factor Axis in Preeclampsia 
 
153 
accelerated proteolysis of IGFBPs [Vatten et al., 2008]. Along with this thesis, a recent study 
demonstrated elevated second trimester levels of PGH in women, who later developed 
preeclampsia associated with intrauterine growth restriction leading to greater availability 
of nutrients for the fetoplacental unit [Papadopoulou et al., 2006]. However, we cannot offer 
an explanation for the apparent delay from first to second trimester for such a placental 
response.  
Regarding the period that follows the clinical manifestation of preeclampsia, IGF-I levels 
seem to markedly decrease in preeclamptic subjects, particularly in the severe subtype of 
this disorder [Halhali et al., 2000; Ingec et al., 2004; Altinkaynak et al., 2003]. Even though it 
could be the result of the compromised production of placental PGH, relative studies based 
on a single point-in –time observations in preeclamptic pregnancies complicated further or 
not by fetal growth restriction are inconsistent and a longitudinal description of the 
correlation between IGF-I and PGH in different trimesters is lacking [Mittal et al., 2007; 
Schiessl et al., 2007] In contrast, two different research groups reported no difference 
between IGF-I values in preeclamptic women and normotensive controls, the one referred to 
preeclamptic women with late-onset disease and the other recruited women with 
preeclampsia of all subtypes [Lewitt et al., 1998].  
2.4 IGFBPs  
2.4.1 IGFBP-1 
A lot of controversy exists regarding the role and the precise mechanisms of action of 
IGFBP-I at the maternal-fetal interface. On the one hand, IGFBP-I may act as a maternal 
restrain to trophoblast invasion via its inhibitory effect on mitogenic IGFs in decidual 
microenvironment [Ritvos et al., 1998]. On the other hand, Gleeson et al. doubt these results 
showing that IGFBP-I potentiates directly the human trophoblast migration by binding of its 
RGD domain (Arg-Gly-Asp) to the ┙5┚1 integrin/fibronectin receptor on invading 
trophoblast leading to activation of mitogen activated protein kinase (MAPK) pathway 
[Gleeson et al., 2001]. This hypothesis is consistent with the observation that the regulation 
of ┙3, ┙5, ┚1, ┚4 integrin subunits (classes of adhesion molecules receptors) in trophoblast 
cells is altered in preeclamptic pregnancies [Zhou et al., 1993]. In vivo, it is still questionable 
which pathway of IGFBP-1 action is deregulated resulting in net suppression on trophoblast 
invasion.    
A possible source of this inconsistency is the altered post-translational modification of 
IGFBP-1 in pregnant women [Forbes & Westwood, 2008]. In the circulation of non-pregnant 
women, IGFBP-1 exists only in its phosphorylated state (p-IGFBP-1) with high affinity for 
IGFs whereas during pregnancy, IGFBP-1 is extensively dephosphorylated to non-
phosphorylated and intermediately phosphorylated isoforms (np-IGFBP-I) with a 6-fold 
lesser binding affinity for IGF-I and similar affinity for IGF-II [Westwood et al., 1994]. The 
functional significance of this modification is highlighted by the finding that np-IGFBP-1 
enhanced the metabolic actions of IGF-I in nutrient transport in contrast to the inhibitory 
phosphorylated isoform [Yu et al., 1998]. A more complete interpretation of the data 
requires consideration of the distribution of the phosphoisoforms of IGFBP-I accompanying 
preeclampsia in each trimester of pregnancy.  
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De Groot et al. were the first who evaluated the midtrimester plasma level of IGFBP-1 in 
pregnancies destined to develop mild/moderate preeclampsia and observed lower 
circulating levels possibly due to the defective placentation that could affect the vascular 
deportation of this protein and/or its reduced hepatic synthesis [De Groot et al., 1996]. A 
more recent study underlined the fact that in a subgroup of women with coexisted White A 
diabetes the concentration of the protein was especially low even before the clinical 
manifestation of the two diseases [Hietala et al., 2000]. This notification implies that 
hyperinsulinemia, an important factor in the pathogenesis of preeclampsia, may 
additionally affect the level of serum IGFBP-1 although their association is still enigmatic.   
In non pregnant women, IGFBP-I is negatively regulated by insulin and prevents glucose 
uptake by muscle and hepatic cells, possibly through IGF-dependent pathways [Holly et al., 
1998]. Therefore decreased IGFBP-I have been related to various states of hyperinsulinemia 
including women with hypertension and insulin resistance. The interconnection of these 
two distinct entities is underlined by a series of well established clinical observations as that 
pregnancy-induced hypertension is more common in women with impaired glucose 
tolerance, pregnant women with diabetes have a higher incidence of preeclampsia and 
hyperinsulinemia can be detected in women several years after their first preeclamptic 
pregnancy [Suhonen & Teramo, 1993]. Surprisingly, other investigators have reported 
normal insulin response to intravenous glucose tolerance tests in preeclamptic women or 
even that these women were more sensitive to insulin [Solomon et al., 1994]. It is theorized 
that the negative relationship between insulin and IGFBP-1, typical of non-pregnant state, 
persists throughout normal pregnancy but seems to be lost in the early stages of pregnancies 
destined to become preeclamptic and either insulin starts to have a stimulatory effect on 
IGFBP-1 or both are regulated by another factor associated to preeclampsia such as hypoxia 
[Anim-Nyame et al., 2003]. However, in a longitudinal study, the circulating IGFBP-1 
concentrations were found to be lower in serial samples obtained from women destined to 
develop preeclampsia indicating that IGFBP-1 is unlikely to act via its IGF-mediated effect 
and may actually promote trophoblast function acting through a signaling IGF-independent 
pathway [Anim-Nyame et al., 2000]. Concurrently, relatively low concentrations of IGFBP-1 
both in the first and second trimesters were related to higher risk of term and in a lesser 
extent for preterm preeclampsia as it is noted in non-pregnant women with a higher 
prevalence of metabolic syndrome [Vatten et al., 2008]. This differentiation may further 
reflect two distinct clinical entities, as preterm preeclampsia is a clinically more severe form 
often accompanied by fetal restricted growth due to the placental disease in contrast to term 
preeclampsia in which placental perfusion and fetal growth are often normal and the main 
pathophysiological processes resemble those of the metabolic syndrome with an increase in 
adipose tissue and impaired glucose and lipid metabolism.  
In pregnancies with established disease, IGFBP-1 levels are grossly elevated in the majority of 
the research studies with older studies supporting a positive correlation with severity of the 
disease and recent studies the opposite [Giudice et al., 1997; Ingec et al., 2004).  This 
fluctuation in serum levels in relation to the clinical onset of preeclampsia has also been 
reported for other placental proteins, such as PAPP-A. Elevated circulating peptide levels may 
reflect the increased synthesis of IGFBP-1 from decidual cells which in turn may play a role in 
the shallow implantation, characteristic of preeclampsia. In another prospective study, IGFBP-I 
concentration was found augmented at the time of delivery only in preeclampsia complicated 
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further by IUGR demonstrating that this change may simply reflect low birthweight in these 
cases or alternatively the higher incidence of IUGR in severe preeclampsia [Wang et al., 1996].  
2.4.2 Other IGFBPs  
In addition to the decidua basalis and parietalis, IGFBP-3, IGFBP-4, and IGFBP-5 are 
expressed in fetal cells with IGFBP-3 being the most prominent [Han et al., 1996]. 
Interestingly, the cleavage of IGFBP-3 into fragments during pregnancy except from 
increasing the availability of IGFs may have additional significance as in the same time these 
fragments can exert IGF-independent biological activity [Firth & Baxter, 2002]. Concerning 
the role of IGFBP-3 in preeclampsia, a study designed to detect genes associated to increased 
apoptosis in preeclamptic placentas showed a strong down regulation pattern leading to 
lower IGF-mediated anti-apoptotic effect causing placental dysfunction [Han et al., 2006]. In 
future, the interaction of some IGFBPs with other placental-produced factors should be also 
investigated. PAPP-A, a useful early marker of preeclampsia, has been identified as protease 
to IGFBP-3 and -4 so its lower levels observed in preeclampsia might diminish the amount 
of IGFs being available for cell uptake and growth stimulation  [Cowans et al., 2007].  
IGFBP-3, the major carrier for IGFs in plasma during pregnancy is the only studied binding 
protein in maternal serum from preeclamptic pregnancies. The only so far published study 
that reported no change in IGFBP-3 levels in early stages of gestation is opposite to recent 
data that demonstrate an increase in IGFBP-3 concentration at 11-13 weeks in term but not 
in preterm preeclampsia not associated to uterine artery PI which is a known measure of 
impaired placental perfusion [Sifakis et al., 2011b]. Most likely, this finding could be the 
result of impaired glucose tolerance and increased insulin resistance as there is in vitro and 
in vivo evidence for a relationship between circulating IGFBP-3 levels and hyperglycemia 
and a IGFBP-3 potent insulin-antagonizing capability exerted either via IGF-independent 
pathways or by decreasing IGF-bioavailability. After the clinical establishment of 
preeclampsia, there is inconsistency among reported results as both a reduction and no 
change in its levels have been demonstrated [Altinkaynak et al., 2003; Wang et al., 1996].  
3. Conclusion 
Overall, it is still uncertain if the deregulation of the tuned balance among IGF system 
components possesses a crucial role in the pathogenesis of preeclampsia or is just a mere 
consequence of the disease. From this summary of relevant research, it is not yet plausible to 
determine the magnitude of possible associations, if any, between varying concentrations of 
IGFs and IGFBPs in maternal circulation and preeclampsia risk. Hopefully, the 
quantification of maternal plasma levels of the peptides of the IGF family may utilize as a 
predictive screening test to select pregnant women at increased risk for developing 
preeclampsia who may be favored from the administration of aspirin or other antiplatelet 
therapy or more intense sonographic surveillance, optimally as the only parameter or 
combined with other known independent indicators of preeclampsia risk. Clearly, much 
additional research is warranted including longitudinal studies with serial measurements of 
these factors and molecular clarification of the signaling pathways of each component 
intending to novel diagnostic interventions and to cast further light on the pathogenesis of 
preeclampsia as well.  
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